

# Checkpoint Inhibitors for Treating Cancer-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/C608B22AB44EN.html>

Date: January 2018

Pages: 150

Price: US\$ 3,480.00 (Single User License)

ID: C608B22AB44EN

## Abstracts

### Report Summary

Checkpoint Inhibitors for Treating Cancer-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Checkpoint Inhibitors for Treating Cancer industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Checkpoint Inhibitors for Treating Cancer 2013-2017, and development forecast 2018-2023

Main market players of Checkpoint Inhibitors for Treating Cancer in EMEA, with company and product introduction, position in the Checkpoint Inhibitors for Treating Cancer market

Market status and development trend of Checkpoint Inhibitors for Treating Cancer by types and applications

Cost and profit status of Checkpoint Inhibitors for Treating Cancer, and marketing status

Market growth drivers and challenges

The report segments the EMEA Checkpoint Inhibitors for Treating Cancer market as:

EMEA Checkpoint Inhibitors for Treating Cancer Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Checkpoint Inhibitors for Treating Cancer Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

PD-1 inhibitors

PD-L1 inhibitors

CTLA-4 inhibitors

EMEA Checkpoint Inhibitors for Treating Cancer Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Melanoma treatment

Bladder cancer treatment

Other

EMEA Checkpoint Inhibitors for Treating Cancer Market: Players Segment Analysis (Company and Product introduction, Checkpoint Inhibitors for Treating Cancer Sales Volume, Revenue, Price and Gross Margin):

Bristol-Myers Squibb(BMS)

Merck

Roche

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF CHECKPOINT INHIBITORS FOR TREATING CANCER**

- 1.1 Definition of Checkpoint Inhibitors for Treating Cancer in This Report
- 1.2 Commercial Types of Checkpoint Inhibitors for Treating Cancer
  - 1.2.1 PD-1 inhibitors
  - 1.2.2 PD-L1 inhibitors
  - 1.2.3 CTLA-4 inhibitors
- 1.3 Downstream Application of Checkpoint Inhibitors for Treating Cancer
  - 1.3.1 Melanoma treatment
  - 1.3.2 Bladder cancer treatment
  - 1.3.3 Other
- 1.4 Development History of Checkpoint Inhibitors for Treating Cancer
- 1.5 Market Status and Trend of Checkpoint Inhibitors for Treating Cancer 2013-2023
  - 1.5.1 EMEA Checkpoint Inhibitors for Treating Cancer Market Status and Trend 2013-2023
  - 1.5.2 Regional Checkpoint Inhibitors for Treating Cancer Market Status and Trend 2013-2023

### **CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Checkpoint Inhibitors for Treating Cancer in EMEA 2013-2017
- 2.2 Consumption Market of Checkpoint Inhibitors for Treating Cancer in EMEA by Regions
  - 2.2.1 Consumption Volume of Checkpoint Inhibitors for Treating Cancer in EMEA by Regions
  - 2.2.2 Revenue of Checkpoint Inhibitors for Treating Cancer in EMEA by Regions
- 2.3 Market Analysis of Checkpoint Inhibitors for Treating Cancer in EMEA by Regions
  - 2.3.1 Market Analysis of Checkpoint Inhibitors for Treating Cancer in Europe 2013-2017
  - 2.3.2 Market Analysis of Checkpoint Inhibitors for Treating Cancer in Middle East 2013-2017
  - 2.3.3 Market Analysis of Checkpoint Inhibitors for Treating Cancer in Africa 2013-2017
- 2.4 Market Development Forecast of Checkpoint Inhibitors for Treating Cancer in EMEA 2018-2023
  - 2.4.1 Market Development Forecast of Checkpoint Inhibitors for Treating Cancer in EMEA 2018-2023
  - 2.4.2 Market Development Forecast of Checkpoint Inhibitors for Treating Cancer by

Regions 2018-2023

## **CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES**

### 3.1 Whole EMEA Market Status by Types

3.1.1 Consumption Volume of Checkpoint Inhibitors for Treating Cancer in EMEA by Types

3.1.2 Revenue of Checkpoint Inhibitors for Treating Cancer in EMEA by Types

### 3.2 EMEA Market Status by Types in Major Countries

3.2.1 Market Status by Types in Europe

3.2.2 Market Status by Types in Middle East

3.2.3 Market Status by Types in Africa

### 3.3 Market Forecast of Checkpoint Inhibitors for Treating Cancer in EMEA by Types

## **CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

4.1 Demand Volume of Checkpoint Inhibitors for Treating Cancer in EMEA by Downstream Industry

4.2 Demand Volume of Checkpoint Inhibitors for Treating Cancer by Downstream Industry in Major Countries

4.2.1 Demand Volume of Checkpoint Inhibitors for Treating Cancer by Downstream Industry in Europe

4.2.2 Demand Volume of Checkpoint Inhibitors for Treating Cancer by Downstream Industry in Middle East

4.2.3 Demand Volume of Checkpoint Inhibitors for Treating Cancer by Downstream Industry in Africa

4.3 Market Forecast of Checkpoint Inhibitors for Treating Cancer in EMEA by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CHECKPOINT INHIBITORS FOR TREATING CANCER**

5.1 EMEA Economy Situation and Trend Overview

5.2 Checkpoint Inhibitors for Treating Cancer Downstream Industry Situation and Trend Overview

## **CHAPTER 6 CHECKPOINT INHIBITORS FOR TREATING CANCER MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA**

- 6.1 Sales Volume of Checkpoint Inhibitors for Treating Cancer in EMEA by Major Players
- 6.2 Revenue of Checkpoint Inhibitors for Treating Cancer in EMEA by Major Players
- 6.3 Basic Information of Checkpoint Inhibitors for Treating Cancer by Major Players
  - 6.3.1 Headquarters Location and Established Time of Checkpoint Inhibitors for Treating Cancer Major Players
  - 6.3.2 Employees and Revenue Level of Checkpoint Inhibitors for Treating Cancer Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 CHECKPOINT INHIBITORS FOR TREATING CANCER MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 7.1 Bristol-Myers Squibb(BMS)
  - 7.1.1 Company profile
  - 7.1.2 Representative Checkpoint Inhibitors for Treating Cancer Product
  - 7.1.3 Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb(BMS)
- 7.2 Merck
  - 7.2.1 Company profile
  - 7.2.2 Representative Checkpoint Inhibitors for Treating Cancer Product
  - 7.2.3 Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin of Merck
- 7.3 Roche
  - 7.3.1 Company profile
  - 7.3.2 Representative Checkpoint Inhibitors for Treating Cancer Product
  - 7.3.3 Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin of Roche

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CHECKPOINT INHIBITORS FOR TREATING CANCER**

- 8.1 Industry Chain of Checkpoint Inhibitors for Treating Cancer
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CHECKPOINT INHIBITORS FOR TREATING CANCER**

- 9.1 Cost Structure Analysis of Checkpoint Inhibitors for Treating Cancer
- 9.2 Raw Materials Cost Analysis of Checkpoint Inhibitors for Treating Cancer
- 9.3 Labor Cost Analysis of Checkpoint Inhibitors for Treating Cancer
- 9.4 Manufacturing Expenses Analysis of Checkpoint Inhibitors for Treating Cancer

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF CHECKPOINT INHIBITORS FOR TREATING CANCER**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Checkpoint Inhibitors for Treating Cancer-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/C608B22AB44EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C608B22AB44EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

